cgt event

Advanced Therapies Week 2026

January 26, 2026

CaseBioscience at Advanced Therapies Week 2026: Beyond Viability

Advanced Therapies Week (ATW) has become a defining meeting for the cell therapy community—bringing together developers, manufacturers, and industry leaders who are shaping how therapies move from concept to clinic and beyond. In 2026, CaseBioscience is proud to participate as a Bronze Sponsor and exhibitor, and we’re excited to engage in conversations that reflect where the field truly is today.

Why ATW Matters to CaseBioscience

Cell therapy has entered an era where early scientific decisions directly influence long-term manufacturing, comparability, and clinical success. At CaseBioscience, we see cryopreservation as a critical part of this continuum—not a downstream step, but a defined process that must support consistency, functional performance, and quality throughout development and manufacturing.

This perspective is central to our work and to our presence at ATW 2026.

Launching CaseCryo® CTG DMSO at ATW

At this year’s meeting, CaseBioscience is officially launching CaseCryo® CTG DMSO, the clinical-use version of our CaseCryo® DMSO Medium.  CaseCryo® CTG DMSO was developed to support cell therapy programs as they progress from development into manufacturing and clinical programs, where process control and reproducibility are essential.

Rather than focusing solely on post-thaw viability, CaseCryo® CTG DMSO is designed with a broader view in mind—supporting functional performance, lot-to-lot consistency, and comparability within controlled quality systems.

Beyond Viability: A Systems-Level View of Cryopreservation

As cell therapies advance, the limitations of viability as a standalone metric become increasingly clear. Cryopreservation must work as part of an integrated workflow—one that considers formulation design, controlled manufacturing, handling, storage, and downstream use as interconnected elements of a single process.

At CaseBioscience, our approach brings together:

  • Medical device–grade manufacturing and quality systems

  • Principles drawn from highly regulated assisted reproductive technology (ART) workflows

  • A systems-level approach that integrates cryopreservation throughout development and manufacturing

This framework allows cryopreservation to function as a reliable, intentional component of the overall cell therapy process.

Bridging ART and Cell Therapy

ART has long operated under stringent controls, where small changes can significantly impact outcomes. By applying lessons from these highly regulated environments, CaseBioscience brings a level of rigor and intentional design to cryopreservation that aligns well with the demands of modern cell therapy programs.

This cross-disciplinary perspective informs not only how our solutions are developed, but how they are manufactured, documented, and supported.

Join the Conversation at ATW

CaseBioscience will be exhibiting at Booth #313, where our team will be available to discuss the CaseCryo® portfolio, including the launch of CaseCryo® CTG DMSO, and our broader approach to cryopreservation across the cell therapy lifecycle.

In addition, CSO Kevin Flynn will be featured in an interview on February 10, sharing insights on why post-thaw viability alone is no longer sufficient—and what developers and manufacturers should be thinking about as therapies continue to mature.

If cryopreservation is part of your development or manufacturing strategy—or if you’re reassessing how it fits as programs advance—we look forward to connecting at Advanced Therapies Week 2026.

Beyond viability. Built for cell therapy.